ACADIA Pharmaceuticals
ACAD
19.65
-0.09
-0.46%
ACADIA Pharmaceuticals
US · ACAD
#2404 by market cap
Listed 1970
19.65
-0.09
-0.46%
Live - 5344 symbols - heartbeat 371s ago
· 2026-10-08 07:15
Pre-market
19.80
+0.75%
After-hours
19.70
+0.25%
- Market cap
- 3.39B
- P/E (TTM)i
- 8.81
- P/Bi
- 2.59
- EPSi
- 2.30
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on ACAD?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 98.93% +0.00pp
- Institutions
- 425
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund51.74%
Hedge Fund40.97%
Public Company2.20%
Government Pension Fund1.07%
VC/PE Fund0.97%
Sovereign Wealth Fund0.97%
Individual/Insider0.55%
Insurance Company0.49%
Private Company0.43%
Other0.60%
Top holders as of 2026-06-30
Baker Bros. Advisors LP
24.91% · 42.91M sh
BlackRock
13.07% · 22.52M sh
State Street Global Advisors
5.27% · 9.08M sh
Vanguard Portfolio Management, LLC
5.13% · 8.84M sh
RTW Investments, LP
4.15% · 7.14M sh
Vanguard Capital Management, LLC
3.87% · 6.68M sh
Dimensional Fund Advisors
2.14% · 3.69M sh
Geode Capital Management, LLC
1.95% · 3.36M sh
Palo Alto Investors LP
1.66% · 2.86M sh
Qube Research & Technologies Ltd
1.42% · 2.45M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 36 buys · 14 sells
| Name | Role | Stake |
|---|---|---|
| Baker Bros. Advisors LP | -- | 24.91% |
| Stephen Davis | Chief Executive Officer | 0.26% |
| Julian Baker | Independent Director | 0.06% |
| Mark Schneyer | Chief Financial Officer | 0.04% |
| Daniel Soland | Independent Director | 0.03% |
| Edmund Harrigan | Independent Director | 0.03% |
| Elizabeth Garofalo | Independent Director | 0.02% |
| Adora Ndu | Independent Director | 0.02% |
| Laura Brege | Independent Director | 0.01% |
| Elizabeth H. Thompson | Executive VP & Head of Research and Development | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-05 | Mark Schneyer | Chief Financial Officer | Derivative Exercise and Sale | -20,141 | $17.84–29.34 |
| 2026-08-04 | Mark Schneyer | Chief Financial Officer | Intent to Sell (Form 144) | -5,849 | $27.15 |
| 2026-07-29 | Elizabeth H. Thompson | Executive VP & Head of Research and Development | Derivative Exercise and Sale | -16,558 | $26.13–26.17 |
| 2026-07-28 | Elizabeth H. Thompson | Executive VP & Head of Research and Development | Derivative Exercise and Retained | +15,714 | -- |
| 2026-06-25 | James Kihara | VP, Chief Accounting Officer & Corporate Controller | Automatic Disposition | -11,421 | $26.08 |
| 2026-05-28 | Laura Brege | Independent Director | Other Derivative Acquisition | +9,311 | -- |
| 2026-05-28 | Laura Brege | Independent Director | Other Derivative Acquisition | +16,004 | $21.66 |
| 2026-05-28 | Laura Brege | Independent Director | Derivative Exercise and Retained | +8,107 | -- |
| 2026-05-28 | Julian Baker | Independent Director | Other Derivative Acquisition | +64,016 | $21.66 |
| 2026-05-28 | Edmund Harrigan | Independent Director | Other Derivative Acquisition | +9,311 | -- |
| 2026-05-28 | Edmund Harrigan | Independent Director | Other Derivative Acquisition | +16,004 | $21.66 |
| 2026-05-28 | Edmund Harrigan | Independent Director | Derivative Exercise and Retained | +8,107 | -- |
| 2026-05-28 | James Daly | Independent Director | Other Derivative Acquisition | +9,311 | -- |
| 2026-05-28 | James Daly | Independent Director | Other Derivative Acquisition | +16,004 | $21.66 |
| 2026-05-28 | James Daly | Independent Director | Derivative Exercise and Retained | +8,107 | -- |
| 2026-05-28 | Baker Bros. Advisors LP | -- | Other Acquisition | +37,244 | -- |
| 2026-05-28 | Jonathan Poole | Director | Other Derivative Acquisition | +9,311 | -- |
| 2026-05-28 | Jonathan Poole | Director | Other Derivative Acquisition | +16,004 | $21.66 |
| 2026-05-28 | Jonathan Poole | Director | Derivative Exercise and Retained | +2,010 | -- |
| 2026-05-28 | Adora Ndu | Independent Director | Other Derivative Acquisition | +9,311 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:15:07 · For reference only, not investment advice and not tailored to your situation.